Sebelipase alfa

N/A

Report date: 2022/03/02 14:28:39

First In Class

Base Information

Drug NameSebelipase alfa

Drug Alias NamerhLAL色贝脂酶α塞贝脂酶αrLALRecombinant human lysosomal acid lipase +[11]

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionLysosomal acid lipase (LAL) enzyme replacementsTriglyceride modulators

TargetsTriglyceride

Therapy Area/IndicationsLysosomal acid lipase deficiencyLysosomal Storage DiseasesWolman Disease +[5]

Global Approved IndicationsLysosomal acid lipase deficiencyLysosomal Storage DiseasesLipid Metabolism, Inborn Errors

Approved Indications in ChinaN/A

Original Approved Country/TerritoryEU

Original Approved Date2015/08/28

Country/TerritoryCzechiaBelgiumCanada +[24]

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsLysosomal acid lipase deficiencyLysosomal Storage DiseasesLipid Metabolism, Inborn Errors

Inactive IndicationsWolman DiseaseCholesterol Ester Storage Disease

ATC CodeA16AB14